The study monitored real-world patient experiences for up to 12 months post cataract surgery with implantation of either AcrySof IQ Vivity or AcrySof IQ Vivity Toric presbyopia-correcting intraocular lens (PCIOL).
Alcon has announced final data from its Vivity Registry Study, which monitored real-world patient experiences for up to 12 months post cataract surgery with implantation of either AcrySof IQ Vivity or AcrySof IQ Vivity Toric presbyopia-correcting intraocular lens (PCIOL).
Alcon stated in a press release, that data from more than 900 cataract patients demonstrated sustained clinical performance, high patient satisfaction and reduced dependence upon spectacles. Alcon also stated that evidence suggested that AcrySof IQ Vivity can be used successfully in a broad range of patients, providing surgeons and patients with additional treatment options.1
The AcrySof IQ Vivity from Alcon is a non-diffractive IOL and uses Alcon’s “proprietary Wavefront-Shaping X-WAVE technology, a next-generation optical principle that stretches and shifts light without splitting it.”
Sunil Vasanth, VP, Europe Surgical Franchise at Alcon discussed IQ Vivity in the press release from Alcon.
“Since its introduction, AcrySof IQ Vivityhas been a disruptive technology—and an innovation we are very proud of as a company. Vivityis a first-of-its kind, non-diffractive extended depth of focus IOL built with our proprietary X-WAVE technology, which stretches and shifts light without splitting it,” said Vasanth. “Our real-world registry data gives surgeons the confidence that Vivity’s performance is sustained over time. This data is also important as it includes patients with common mild comorbidities like glaucoma, dry eye and retinopathy/maculopathy.”
The Vivity Registry Study was a multicentre, ambispective, non-comparative, open-label, non-interventional registry study conducted across 41 sites from 8 countries.1
Results from the Vivity Registry Study included:1